Jaguar nabs Merck pro to lead development; NexVet partners with Zenoaq; Schein buys half of Romanian distributor Maravet;

> Jaguar Animal Health ($JAGX) named Merck ($MRK) veteran Victoria Lewis as its chief of clinical development. Release

> NexVet Biopharma ($NVET) has signed a research partnership with Japan's Zenoaq to develop immuno-oncology and allergy/inflammation treatments for pets. Release

> Henry Schein ($HSIC) has purchased a 50 percent stake of Maravet, an animal health distributor in Romania with $23 million in annual sales. Release

> A coalition of farming and veterinary groups in the U.K. have submitted a proposal outlining a new approach to handling bovine tuberculosis and non-statutory cattle diseases in England. Article

> The USDA has issued its final rule for amending the Virus-Serum-Toxin Act in a way that will simplify the labeling of biologics going forward. Document (PDF)

> Neogen ($NEOG) has expanded its relationship with Illumina ($ILMN), which will market and sell arrays using Neogen's custom SNP content to agriculture producers. Release

> The USDA is warning veterinarians and producers in the west of reports of vesicular stomatitis (VS), an insect-borne virus that is affecting horses and livestock. Article

> The U.K.'s Eco Animal Health reported that strong sales of Aivlosin, its antibiotic for pigs and poultry, helped push worldwide sales for the year ended in March up 30%. Article

> Stella & Chewy's is recalling some of its food products for dogs and cats due to the discovery of Listeria monocytogenes in one of its products. Release

> Scientists from the University Of Edinburgh and the Centre For Ecology And Hydrology have published a study showing that infections in wild birds can impact the health and well-being of flock-mates--even those that do not have the illness. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…